clinical trial · NCT07303296
Efficacy and Safety Study of Bilateral IVT Injection of GS010 at Two Dose Levels in LHON Patients
GenSight Biologics·phase2·recruiting·n = 14
Leber Hereditary Optic DiseaseGS010 High doseGS010 Low dose
brief summary
The goal of this Clinical trial is to assess the safety and efficacy of GS010 at two dose levels on visual acuity and retinal mitochondrial activity in patients affected with ND4 Leber Hereditary Optic Neuropathy (LHON)
started
Jan 22, 2026
primary completion
May 15, 2028
completion
Jun 1, 2028
last updated
Mar 2, 2026
official title
A Dose-ranging Randomized, Open-label Study Evaluating the Effect of Bilateral Intravitreal Injection of GS010 at Two Dose Levels on Visual Acuity and Retinal Mitochondrial Activity in Patients Affected With ND4 Leber Hereditary Optic Neuropathy - The REVISE Study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol